Regeneron Pharmaceuticals Inc. buy Citigroup Inc.
Summary
This prediction ended on 15.05.26 with a price of €613.30. The prediction had a final performance of 17.99%. Citigroup_Inc_ has a follow-up prediction for Regeneron Pharmaceuticals Inc. where he still thinks Regeneron Pharmaceuticals Inc. is a Buy. A total of €3.58 was paid as dividends for this prediction. Citigroup_Inc_ has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | -0.600% | -0.600% | 40.335% |
| iShares Core DAX® | -0,05 % | 5,96 % | 7,40 % |
| iShares Nasdaq 100 | 0,92 % | 3,69 % | 28,14 % |
| iShares Nikkei 225® | 3,01 % | 6,64 % | 48,89 % |
| iShares S&P 500 | -0,36 % | 2,75 % | 22,53 % |
Comments by Citigroup_Inc_ for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
In the thread Trading Regeneron Pharmaceuticals Inc.
Current prediction by Citigroup_Inc_ for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
13.10.25
13.10.26
07:30
Stopped prediction by Citigroup_Inc_ for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
29.10.25
29.10.26
07:30
Regeneron Pharmaceuticals Inc.
02.06.25
02.06.26
03.06.26

